Biological correlates of FDG uptake in non-small cell lung cancer

Lung Cancer

Volumn 55, Issue 1, 2007, Pages 79-87

  de Geus Oei, Lioe Fee ^a   Krieken, J Han J M van ^a   Aliredjo, Riena P ^a   Krabbe, Paul F M ^a   Frielink, Cathelijne ^a   Verhagen, Ad F T ^a   Boerman, Otto C ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Caspase 3; Early stage NSCLC; FDG PET; GLUT; Hexokinase; SUV; Tumor size

Indexed keywords

CASPASE 3; CYSTEINE PROTEINASE; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLYCOLYTIC ENZYME; HEXOKINASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACCUMULATION; DRUG UPTAKE; EVALUATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MALE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STANDARD; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE NECROSIS; TISSUE SECTION; TUMOR CELL;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 2; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; RADIOPHARMACEUTICALS;

EID: 33845932831     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.08.018     Document Type: Article

References (49)

1. Vansteenkiste J., Fischer B.M., Dooms C., and Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 5 (2004) 531-540
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
3. Kopp R., Weidenhagen R., Reinmiedl J., Muller C., Furst H., Bittmann I., et al. Outcome following lung resections for pT1 non-small cell lung cancer. Eur J Surg Oncol 32 (2006) 329-334
4. Vokes E. Seeking improved outcome in the curative treatment of non-small-cell lung cancer. Lung Cancer 50 Suppl. 1 (2005) S20-S22
5. Endo S., Tsubochi H., Tetsuka K., Sato Y., Hasegawa T., Otani S., et al. Preoperative chemotherapy for cStage III-pN0 patients with non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 54 (2006) 109-113
6. Rigas J.R., and Lara Jr. P.N. Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. Lung Cancer 50 Suppl. 2 (2005) S17-S24
7. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
8. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
9. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
10. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
11. van Rens M.T., de la Riviere A.B., Elbers H.R., and van den Bosch J.M. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117 (2000) 374-379
12. Watanabe Y. TNM classification for lung cancer. Ann Thorac Cardiovasc Surg 9 (2003) 343-350
13. Jones D.R., Daniel T.M., Denlinger C.E., Rundall B.K., Smolkin M.E., and Wick M.R. Stage IB nonsmall cell lung cancers: are they all the same?. Ann Thorac Surg 81 (2006) 1958-1962
14. Verhagen A.F., Bootsma G.P., Tjan-Heijnen V.C., van der Wilt G.J., Cox A.L., Brouwer M.H., et al. FDG-PET in staging lung cancer: how does it change the algorithm?. Lung Cancer 44 (2004) 175-181
15. van Tinteren H., Hoekstra O.S., Smit E.F., van den Bergh J.H., Schreurs A.J., Stallaert R.A., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359 (2002) 1388-1393
16. Pieterman R.M., van Putten J.W., Meuzelaar J.J., Mooyaart E.L., Vaalburg W., Koeter G.H., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343 (2000) 254-261
17. Vesselle H., Turcotte E., Wiens L., Schmidt R., Takasugi J.E., Lalani T., et al. Relationship between non-small cell lung cancer fluorodeoxyglucose uptake at positron emission tomography and surgical stage with relevance to patient prognosis. Clin Cancer Res 10 (2004) 4709-4716
18. Juweid M.E., and Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354 (2006) 496-507
19. Younes M., Brown R.W., Stephenson M., Gondo M., and Cagle P.T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80 (1997) 1046-1051
20. Kunkel M., Reichert T.E., Benz P., Lehr H.A., Jeong J.H., Wieand S., et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97 (2003) 1015-1024
21. Smith T.A. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun 19 (1998) 97-105
22. Akhurst T., Kates T.J., Mazumdar M., Yeung H., Riedel E.R., Burt B.M., et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 23 (2005) 8713-8716
23. Duhaylongsod F.G., Lowe V.J., Patz Jr. E.F., Vaughn A.L., Coleman R.E., and Wolfe W.G. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60 (1995) 1348-1352
24. Vesselle H., Schmidt R.A., Pugsley J.M., Li M., Kohlmyer S.G., Vallires E., et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6 (2000) 3837-3844
25. Arai T., Kuroishi T., Saito Y., Kurita Y., Naruke T., and Kaneko M. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol 24 (1994) 199-204
26. Usuda K., Saito Y., Sagawa M., Sato M., Kanma K., Takahashi S., et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 74 (1994) 2239-2244
27. Tirindelli-Danesi D., Teodori L., Mauro F., Modini C., Botti C., Cicconetti ., et al. Prognostic significance of flow cytometry in lung cancer. A 5-year study. Cancer 60 (1987) 844-851
28. Gallego M.A., Joseph B., Hemstrom T.H., Tamiji S., Mortier L., Kroemer G., et al. Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas. Oncogene 23 (2004) 6282-6291
29. Sasaki R., Komaki R., Macapinlac H., Erasmus J., Allen P., Forster K., et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23 (2005) 1136-1143
30. Takata T., Tanaka F., Yamada T., Yanagihara K., Otake Y., Kawano Y., et al. Clinical significance of caspase-3 expression in pathologic-stage I, nonsmall-cell lung cancer. Int J Cancer 96 Suppl. 54-60 (2001) 96
31. Clavo A.C., Brown R.S., and Wahl R.L. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 36 (1995) 1625-1632
32. Mamede M., Higashi T., Kitaichi M., Ishizu K., Ishimori T., Nakamoto Y., et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 7 (2005) 369-379
33. Lee J.D., Yang W.I., Park Y.N., Kim K.S., Choi J.S., Yun M., et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med 46 (2005) 1753-1759
34. Pan C.C., Chen P.C., and Chiang H. An easy method for manual construction of high-density tissue arrays. Appl Immunohistochem Mol Morphol 12 (2004) 370-372
35. Higashi K., Ueda Y., Sakurai A., Wang X.M., Xu L., Murakami M., et al. Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med 27 (2000) 1778-1785
36. Marom E.M., Aloia T.A., Moore M.B., Hara M., Herndon J.E., Harpole Jr. D.H., et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 33 (2001) 99-107
37. Chung J.K., Lee Y.J., Kim S.K., Jeong J.M., Lee D.S., and Lee M.C. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 25 (2004) 11-17
38. Brown R.S., Leung J.Y., Kison P.V., Zasadny K.R., Flint A., and Wahl R.L. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 40 (1999) 556-565
39. Chung J.H., Cho K.J., Lee S.S., Baek H.J., Park J.H., Cheon G.J., et al. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging. J Nucl Med 45 (2004) 999-1003
40. Eschmann S.M., Friedel G., Paulsen F., Reimold M., Hehr T., Budach W., et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?. Eur J Nucl Med Mol Imaging 33 (2006) 263-269
41. Ahuja V., Coleman R.E., Herndon J., and Patz Jr. E.F. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83 (1998) 918-924
42. Downey R.J., Akhurst T., Gonen M., Vincent A., Bains M.S., Larson S., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22 (2004) 3255-3260
43. Dhital K., Saunders C.A., Seed P.T., O'Doherty M.J., and Dussek J. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 18 (2000) 425-428
44. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., De Leyn P.R., Verbeken E.K., Deneffe G.J., et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17 (1999) 3201-3206
45. Jeong H.J., Min J.J., Park J.M., Chung J.K., Kim B.T., Jeong J.M., et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23 (2002) 865-870
46. Higashi K., Ueda Y., Arisaka Y., Sakuma T., Nambu Y., Oguchi M., et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 43 (2002) 39-45
47. Yasuda S., Arii S., Mori A., Isobe N., Yang W., Oe H., et al. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. J Hepatol 40 (2004) 117-123
48. Haberkorn U., Bellemann M.E., Brix G., Kamencic H., Morr I., Traut U., et al. Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med 28 (2001) 418-425
49. Ishikawa N., Oguri T., Isobe T., Fujitaka K., and Kohno N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res 92 (2001) 874-879